Pharmaceuticals, Biotechnology and Life Sciences
Ridgeback Biotherapeutics announces the start of enrollment in a Phase 2 trial of potential COVID-19 treatment EIDD-2801.
Astex Pharmaceuticals, Inc.; Taiho Oncology, Inc.; and Otsuka Pharmaceutical Co., Ltd. today announce that the U.S. Food and Drug Administration (FDA) and Health Canada have approved INQOVI® (decitabine and cedazuridine) tablets. The three companies are all part of the Otsuka group of companies.
Arcus Biosciences, an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that Bob Goeltz will join Arcus as Chief Financial Officer
Tenax Therapeutics in $8 million registered direct and pipe offerings priced at the market under Nasdaq rules
Remdevisir has become a popular word these days, along with Covid-19, Coronavirus, the city of Wuhan, and for a good reason. The headline in all the news, the pricing of remdevisir, has been flooding the internet, and pretty much the TV.
NuvOx Pharma ensured the continuation of Phase 2 clinical trial of its NanO2 in Covid-19 patients with acute hypoxic respiratory failure, as it got No Objection Letter from Health Canada.
Arya and Immatics’s previouslly announced business combination into combined company called Immatics N.V., has been approved by both companies’ shareholders,…
Seattle Genetics’ results from the phase 2 of trial testing tisotumab vedotin to treat patients with relapsed or progressed metastatic cervical cancer, showed clinically meaningful and durable objective responses with a manageable safety profile.
Rocket Pharmaceuticals has received clearance from the U.S. Food and Drug Administration (FDA) for the Company’s Investigational New Drug (IND) application for RP-L401, its, lentiviral vector (LVV)-based gene therapy for the treatment of Infantile Malignant Osteopetrosis (IMO), a rare, severe monogenic bone resorption disorder.
NanoImaging Services (NIS) said on Thursday that it is opening a new facility in Boston to support its growing customer base requiring cryoEM for drug discovery and vaccine development applications. COVID-19 projects are receiving prioritization.